Curaleaf Delays Fourth-Quarter and Fiscal-Year 2022 Earnings Release
Curaleaf’s CURA fourth-quarter and full-year 2022 earnings release was originally set for March 28. On March 24, the company announced a delay until some date in April, yet to be announced. The company cited complexities with converting to U.S. GAAP from IFRS reporting standards as the main reason for the delay.
For now, our fair value estimates of $25 and CAD 34 per share are unchanged for no-moat Curaleaf. However, we will wait for Curaleaf’s full release for a complete understanding and any potential changes.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.